Golfblues, I don't know if this holds true in EKSO's circumstance. Back in the day when 80% of bio-tech companies blew up either by FDA non clearance or ran out of cash. One of the reasons for there demise was the PHd. or MD who evented the drug ( and were usually brilliant) usually held the president and CEO positions .The problem was they couldn't run a company worth a darn. Additionally It's not good if they didn't part as friends, we can only speculate. So lets hope indeed that the new management team will have success, were betting on it...